Christopher J. Schultz, MD

Publications

• The impact of age on outcome in phase III NRG Oncology/RTOG trials of radiotherapy (XRT) +/- systemic therapy in locally advanced head and neck cancer.

  (Kish JA, Zhang Q, Langer CJ, Nguyen-Tân PF, Rosenthal DI, Weber RS, List MA, Wong SJ, Garden AS, Hu K, Trotti AM, Bonner JA, Jones CU, Yom SS, Thorstad W, Schultz CJ, Ridge JA, Shenouda G, Harris J, Le QT.) J Geriatr Oncol. 2021 Jul;12(6):937-944 PMID: 33814339 SCOPUS ID: 2-s2.0-85103725742 04/06/2021

• BRCA1 Protein Expression Predicts Survival in Glioblastoma Patients from an NRG Oncology RTOG Cohort.

  (Vassilakopoulou M, Won M, Curran WJ, Souhami L, Prados MD, Langer CJ, Rimm DL, Hanna JA, Neumeister VM, Melian E, Diaz AZ, Atkins JN, Komarnicky LT, Schultz CJ, Howard SP, Zhang P, Dicker AP, Knisely JPS.) Oncology. 2021 May 06:1-9 PMID: 33957633 05/07/2021

• Risk groups of laryngeal cancer treated with chemoradiation according to nomogram scores - A pooled analysis of RTOG 0129 and 0522.

  (Awan MJ, Gittleman H, Barnholtz-Sloan J, Machtay M, Nguyen-Tan PF, Rosenthal DI, Schultz C, Huth BJ, Thorstad WL, Frank SJ, Kim H, Foote RL, Lango MN, Shenouda G, Suntharalingam M, Harris J, Zhang Q, Le QT, Yao M, NRG Oncology Group.) Oral Oncol. 2021 May;116:105241 PMID: 33640577 PMCID: PMC8144062 SCOPUS ID: 2-s2.0-85101423773 03/01/2021

• In Reply to Peñagarícano.

  (Bovi JA, Schultz CJ.) Int J Radiat Oncol Biol Phys. 2021 02 01;109(2):641 PMID: 33422280 SCOPUS ID: 2-s2.0-85098481483 01/11/2021

• Prognostic Significance of IDH1/2 Mutation and MGMT Promoter Methylation Status in RTOG 9813.

  (Fleming JL, Pugh S, Bell EH, Chang SM, McElroy J, Becker A, Timmers CD, Shih HA, Ashby L, Hunter GK, Bahary JP, Schultz CJ, Kavanagh BD, Yung WA, Robins I, Werner-Wasik M, Chakravarti A.) Int J Radiat Oncol Biol Phys. 2020 12 01;108(5):1399 PMID: 33427658 SCOPUS ID: 2-s2.0-85100069396 01/12/2021

• Comprehensive Genomic Analysis in NRG Oncology/RTOG 9802: A Phase III Trial of Radiation Versus Radiation Plus Procarbazine, Lomustine (CCNU), and Vincristine in High-Risk Low-Grade Glioma.

  (Bell EH, Zhang P, Shaw EG, Buckner JC, Barger GR, Bullard DE, Mehta MP, Gilbert MR, Brown PD, Stelzer KJ, McElroy JP, Fleming JL, Timmers CD, Becker AP, Salavaggione AL, Liu Z, Aldape K, Brachman DG, Gertler SZ, Murtha AD, Schultz CJ, Johnson D, Laack NN, Hunter GK, Crocker IR, Won M, Chakravarti A.) J Clin Oncol. 2020 10 10;38(29):3407-3417 PMID: 32706640 PMCID: PMC7527157 SCOPUS ID: 2-s2.0-85092564201 07/25/2020

• The MOMENTUM Study: An International Registry for the Evidence-Based Introduction of MR-Guided Adaptive Therapy.

  (de Mol van Otterloo SR, Christodouleas JP, Blezer ELA, Akhiat H, Brown K, Choudhury A, Eggert D, Erickson BA, Faivre-Finn C, Fuller CD, Goldwein J, Hafeez S, Hall E, Harrington KJ, van der Heide UA, Huddart RA, Intven MPW, Kirby AM, Lalondrelle S, McCann C, Minsky BD, Mook S, Nowee ME, Oelfke U, Orrling K, Sahgal A, Sarmiento JG, Schultz CJ, Tersteeg RJHA, Tijssen RHN, Tree AC, van Triest B, Hall WA, Verkooijen HM.) Front Oncol. 2020;10:1328 PMID: 33014774 PMCID: PMC7505056 10/06/2020

• Improving Structure Delineation for Radiation Therapy Planning Using Dual-Energy CT.

  (Noid G, Zhu J, Tai A, Mistry N, Schott D, Prah D, Paulson E, Schultz C, Li XA.) Front Oncol. 2020;10:1694 PMID: 32984048 PMCID: PMC7484725 09/29/2020

• The MOMENTUM Study: An International Registry for the Evidence-Based Introduction of MR-Guided Adaptive Therapy

  (de Mol van Otterloo SR, Christodouleas JP, Blezer ELA, Akhiat H, Brown K, Choudhury A, Eggert D, Erickson BA, Faivre-Finn C, Fuller CD, Goldwein J, Hafeez S, Hall E, Harrington KJ, van der Heide UA, Huddart RA, Intven MPW, Kirby AM, Lalondrelle S, McCann C, Minsky BD, Mook S, Nowee ME, Oelfke U, Orrling K, Sahgal A, Sarmiento JG, Schultz CJ, Tersteeg RJHA, Tijssen RHN, Tree AC, van Triest B, Hall WA, Verkooijen HM.) Frontiers in Oncology. 7 September 2020;10 SCOPUS ID: 2-s2.0-85091425211 09/07/2020

• Improving Structure Delineation for Radiation Therapy Planning Using Dual-Energy CT

  (Noid G, Zhu J, Tai A, Mistry N, Schott D, Prah D, Paulson E, Schultz C, Li XA.) Frontiers in Oncology. 28 August 2020;10 SCOPUS ID: 2-s2.0-85090756213 08/28/2020

• Initial clinical experience of Stereotactic Body Radiation Therapy (SBRT) for liver metastases, primary liver malignancy, and pancreatic cancer with 4D-MRI based online adaptation and real-time MRI monitoring using a 1.5 Tesla MR-Linac.

  (Hall WA, Straza MW, Chen X, Mickevicius N, Erickson B, Schultz C, Awan M, Ahunbay E, Li XA, Paulson ES.) PLoS One. 2020;15(8):e0236570 PMID: 32764748 PMCID: PMC7413561 SCOPUS ID: 2-s2.0-85089301005 08/09/2020

• 4D-MRI driven MR-guided online adaptive radiotherapy for abdominal stereotactic body radiation therapy on a high field MR-Linac: Implementation and initial clinical experience

  (Paulson ES, Ahunbay E, Chen X, Mickevicius NJ, Chen GP, Schultz C, Erickson B, Straza M, Hall WA, Li XA.) Clinical and Translational Radiation Oncology. July 2020;23:72-79 SCOPUS ID: 2-s2.0-85084968086 07/01/2020